Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Mesonephric-like Adenocarcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Detailed description
Primary Objectives
1\. To collect data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA).
Secondary Objectives
1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome. 2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.
Primary outcome measures
- Tumor Registry [Time frame: Through study completion; an average of 1 year]
Eligibility criteria
Inclusion criteria
- Adult patients over the age of 18.
- Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas.
- For patients who provide consent, they must speak and/or read English or Spanish.
Exclusion criteria
- Patients with other subtypes of EACs.
- Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- MD Anderson Cancer Center — Houston
Identifiers
NCT: NCT06377527 · 2023-0945 · NCI-2024-03342